Work

Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy

Year: 2024

Type: article

Abstract: We read with interest the study by El Messaoudi et al.1 analyzing and mathematically modeling serum HDV RNA and biochemical (ALT) kinetics during therapy with the entry inhibitor bulevirtide (BLV) alone or in combination with pegylated interferon (Peg-IFN). The authors analyzed an impressive amount of kinetic data from 183 treated patients (114 BLV; 69 BLV+Peg-IFN) who participated in two French multicenter cohort studies. They used a mathematical model to estimate BLV efficacy in blocking infection (parameter η) and viral and host kinetic parameters, such as the loss rate of HDV-infected cells (parameter δ), to predict the optimal duration of BLV-based treatment and rate of cure.

Source: JHEP Reports

DOI: 10.1016/j.jhepr.2024.101211

Authors: Adquate Mhlanga, Ori Wasserman, Pietro Lampertico, Scott J. Cotler, Harel Dahari

Institutions: Loyola University Chicago, Loyola Medicine, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Language: English

Topic: Hepatitis B Virus Studies

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,900